Dissertations / Theses on the topic 'Cancer treatment'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Cancer treatment.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Tong, Ka-keung. "Cancer Treatment Centre." Click to view the E-thesis via HKUTO, 1996. http://sunzi.lib.hku.hk/hkuto/record/B31983066.
Full textIncludes special report study entitled : Hospital planning study for the cancer treatment centre. Includes bibliographical references. Also available in print.
Tong, Ka-keung, and 唐家強. "Cancer Treatment Centre." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1996. http://hub.hku.hk/bib/B31983066.
Full textCha, Kyungduck. "Cancer treatment optimization." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2008. http://hdl.handle.net/1853/22604.
Full textCommittee Chair: Lee, Eva K.; Committee Member: Barnes, Earl; Committee Member: Hertel, Nolan E.; Committee Member: Johnson, Ellis; Committee Member: Monteiro, Renato D.C.
Горобченко, Неля Георгіївна, Неля Георгиевна Горобченко, Nelia Heorhiivna Horobchenko, and T. Loboda. "Progress in cancer treatment." Thesis, Вид-во СумДУ, 2009. http://essuir.sumdu.edu.ua/handle/123456789/16753.
Full textГоробченко, Неля Георгіївна, Неля Георгиевна Горобченко, Nelia Heorhiivna Horobchenko, and T. Loboda. "Progress in cancer treatment." Thesis, Видавництво СумДУ, 2009. http://essuir.sumdu.edu.ua/handle/123456789/7209.
Full textReuille, Kristina M. "Cancer Treatment-Related Fatigue: Psychometric Testing of the Cancer Treatment-Related Fatigue Representation Scale (CTRFRep) in Patients Undergoing Radiation Treatment for Cancer." Thesis, Connect to resource online, 2009. http://hdl.handle.net/1805/2069.
Full textTitle from screen (viewed on February 2, 2010). School of Nursing, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): Janet L. Welch, Juanita F. Keck, Janet S. Fulton, Barbara Manz Friesth. Includes vitae. Includes bibliographical references (leaves 150-164).
Aubert-Jürgens, Ana. "STAT3 inhibitors for cancer treatment." [S.l.] : [s.n.], 2005. http://elib.tu-darmstadt.de/diss/000563.
Full textJohansson, David. "Bacterial toxins for cancer treatment." Doctoral thesis, Umeå universitet, Medicinsk biovetenskap, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1637.
Full textBasran, Parminder S. "Optimisation of lung cancer treatment." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/mq22568.pdf.
Full textWirth, Manfred P., and Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133890.
Full textDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Abusara, Osama. "Neuropeptide antagonists for cancer treatment." Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/neuropeptide-antagonists-for-cancer-treatment(e2f22b9f-f0a7-432d-89c4-7e65a2c71b69).html.
Full textWirth, Manfred P., and Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer." Karger, 1999. https://tud.qucosa.de/id/qucosa%3A27546.
Full textDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
Whitehouse, Pauline Amanda. "Integrated individualised treatment of colorectal cancer." Thesis, University College London (University of London), 2005. http://discovery.ucl.ac.uk/1446884/.
Full textLi, Pei-Xiang. "Molecular approaches to breast cancer treatment." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape7/PQDD_0023/NQ50092.pdf.
Full textAbraham, J. E. "The pharmacogenetics of breast cancer treatment." Thesis, University of Cambridge, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.595327.
Full textCunningham, David. "Gastric cancer : natural history and treatment." Thesis, University of Glasgow, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.293449.
Full textLinardakis, Emmanouela. "Developing immunotherapy strategies for cancer treatment." Thesis, Open University, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.396819.
Full textUllal, Adeeti (Adeeti Vedantham). "Micro and nanotechnology for cancer treatment." Thesis, Massachusetts Institute of Technology, 2013. http://hdl.handle.net/1721.1/83968.
Full textCataloged from PDF version of thesis.
Includes bibliographical references (pages 92-101).
Cancer is responsible for over 7.6 million deaths worldwide; the majority of patients fail to respond to drugs or become resistant over time. In order to gain a better understanding of drug efficacy in patients, we developed three diagnostic technologies to address limitations in sample acquisition and improve the scale and sensitivity of current cancer diagnostic tools. In the first section, we describe a hybrid magnetic and size sorting microfluidic device that isolates rare circulating tumor cells from peripheral blood. The self-assembled magnetic sorter creates strong magnetic fields and effectively removes leukocytes tagged with magnetic nanoparticles. The size sorting region retains the remaining cells in single cell capture sites, while allowing small red blood cells to pass through 5pm gaps. The device achieves over 103 enrichment, up to 96% recovery of cancer cells and allows for on-chip molecular profiling. In the second section we use a magnetic nanoparticle decorated with small molecule drugs to assay target expression and drug binding in mock clinical samples of cancer cells spiked into whole blood. Specifically, we modify a PARP inhibitor (Olabarib) and conjugate it to a dextran coated iron oxide nanoparticle. We measure the presence of the drug nanosensor based on the change in T2 relaxation time using a miniaturized, handheld NMR sensor for point-of-care diagnosis. In the final section, we detail a photocleavable DNA barcoding method for understanding treatment response via multiplexed profiling of cancer cells. We validate our method with a 94 marker panel on different cell lines with varying treatments, showing high correlations to gold standard methods such as immunofluorescence and flow cytometry. Furthermore, we demonstrate single cell sensitivity, and identify a number of expected biomarkers in response to cell treatments. Finally, we demonstrate the potential of our method to help in clinical monitoring of patients by examining intra- and inter-patient heterogeneity, and by correlating pre and post-treatment tumor profiles to patient response. Together, we show how these technologies can help overcome clinical limitations and expedite advancements in cancer treatment.
by Adeeti Ullal
Ph.D.in Biomedical Engineering
Kho, Sunn Sunn Patricia. "Optimising Adjuvant Treatment for Colorectal Cancer." Thesis, The University of Sydney, 2013. http://hdl.handle.net/2123/9470.
Full textChen, Zong-Ping. "Three-dimensional hyperthermia cancer treatment simulation." Diss., The University of Arizona, 1989. http://hdl.handle.net/10150/184852.
Full textEbeid, Kareem Atef Nassar. "Nanoparticles for targeted treatment of cancer." Diss., University of Iowa, 2018. https://ir.uiowa.edu/etd/6567.
Full textJakobi, Annika. "Evaluation of proton treatment strategies for head and neck cancer and lung cancer based on treatment planning studies." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-207484.
Full textDie Einführung der Protonentherapie in die klinische Praxis erfordert umfassende Analysen ihrer Vor- und Nachteile im Vergleich zur konventionellen Photonentherapie sowie detaillierte Untersuchungen der Auswirkungen von Unsicherheiten in der Therapieapplikation. Im ersten Teil der vorliegenden Arbeit wurden die zu erwartenden Nebenwirkungen bei der Behandlung von Patienten mit Kopf-Hals-Tumoren mit einem biologisch-adaptierten Fraktionierungsschema inklusive Dosiseskalation mit Photonen- und Protonentherapie evaluiert. Dabei konnte gezeigt werden, dass die Dosiseskalation sowohl mit Photonen- als auch Protonentherapie angewandt werden kann, da die Wahrscheinlichkeit für das Auftreten von Nebenwirkungen in den meisten Fällen kaum erhöht wurde. Weiterhin wurden die Nebenwirkungswahrscheinlichkeiten mit der Protonentherapie im Vergleich zur Photonentherapie reduziert. Dies war vor allem für Patienten mit Tumoren im oberen Kopf-Hals-Bereich der Fall. Diese könnten daher bevorzugt zur Protonentherapie überwiesen werden. Darüber hinaus wurde im zweiten Teil der Arbeit eine umfassende Analyse des Einflusses der Tumorbewegung auf die Dosisverteilung bei Behandlung von Lungentumoren mit aktiver Protonenstrahlformierung durchgeführt. Dabei zeigte sich, dass Dosisdegradierungen bei Bewegungsamplituden unter 5mm gering sind. Parameter wie das Zielvolumenkonzept, Veränderungen des Bewegungsmusters oder der Applikationszeiten nehmen zusätzlich Einfluss auf die Dosisdegradierung, allerdings in unterschiedlichem Maß für individuelle Patienten. Da nicht alle Parameter vor Behandlung bekannt sein können, sollten prospektive Dosisabschätzungen durch retrospektive Analysen ergänzt werden
Chiwakata, Maynard Tendai. "The synthesis and breast cancer inhibitory activity of cinnamic acid analogues based on the halogenated monoterpene pharmacophore." Thesis, Rhodes University, 2012. http://hdl.handle.net/10962/d1016129.
Full textKikkawa, Fumitaka, Akihiro Nawa, Kazuhiko Ino, Kiyosumi Sibata, Hiroaki Kajiyama, Seiji Nomura, 史隆 吉川, et al. "Advances in treatment of epithelial ovarian cancer." Nagoya University School of Medicine, 2006. http://hdl.handle.net/2237/6129.
Full textThanoon, David. "Computational framework for local breast cancer treatment." Thesis, Bordeaux 1, 2011. http://www.theses.fr/2011BOR14387/document.
Full textBreast cancer is the most common cancer among women in the developed as well as the developing countries. There are a plethora of proposed solutions regarding possible medical interventions for breast cancer–one in particular is Breast Conserving Therapy (BCT). BCT comprises of complete surgical excision of the tumor (partialmastectomy), and post-operative radiotherapy for the remaining breast tissue. This is a feasible treatment for most women with breast cancer. The goal of BCT is toachieve local control of the cancer, as well as to preserve breast shape that appeases awoman’s cosmetic concerns. Although these goals are usually achieved, there are still occasional unexpected results, such as reexcision of the tumor due to a positive margin assessment, tumor local recurrence, unsatisfactory cosmetic results, and breastpain. Other than surgical experience and judgment, there are currently no toolswhich can predict the outcome of partial mastectomy on the contour and deformity of the treated breast. The objective of this dissertation is to propose computational framework, which contributes to BCT operations, this was achieve by exploring two areas.On the one hand we developed a multiscale model adapted for breast cancer tumor growth, ductal carcinoma in situ (DCIS). The model features included: nutrients growth limitation, wall degradation enzyme and HER2 chemical expression tumor phenotype. Our model successfully simulate some pattern of DCIS carcinoma.Among the interesting result we showed that the enzyme contributed to a greater tumor size and that when HER2 was over expressed, the growth limiting factor wasthe EGFR. On the other hand, we developed a virtual surgery box to simulate BCT surgery. The box will input MRI patient data and will output cosmetic and functional indicator to rate the impact of the surgery. It appears that stiffness of the tissue, resection radius as well as the lump quadrant location are the most sensitive parameters to the indicators. A healing model was also embedded to simulate the wound closure after resection, this model was stress dependent and illustrate anasymmetric wound closure progression.The tools developed in this research allows a new type of field convergence between the surgery and computation field. At the local level it will allow surgeons and patient to be able to communicate on the pertinence and necessity of performing alumpectomy surgery, enabling to anticipate the possible outcome of the operation.On the global aspect this type of tool gives birth to a new type of field: computational surgery, where computer scientist and surgeons work hand in hand to provide the best and the most reliable service to the patients
Roxburgh, Patricia. "Manipulating the p53 pathway for cancer treatment." Thesis, University of Glasgow, 2013. http://theses.gla.ac.uk/4576/.
Full textWirth, Manfred P., and Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133839.
Full textWhitman, Birgit. "Breast cancer : patient narratives and treatment methods." Thesis, University of Glasgow, 2004. http://theses.gla.ac.uk/2969/.
Full textSilberholz, John. "Analytics for Improved Cancer Screening and Treatment." Thesis, Massachusetts Institute of Technology, 2015. http://hdl.handle.net/1721.1/101290.
Full textThis electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.
Cataloged from student-submitted PDF version of thesis.
Includes bibliographical references (pages 139-156).
Cancer is a leading cause of death both in the United States and worldwide. In this thesis we use machine learning and optimization to identify effective treatments for advanced cancers and to identify effective screening strategies for detecting early-stage disease. In Part I, we propose a methodology for designing combination drug therapies for advanced cancer, evaluating our approach using advanced gastric cancer. First, we build a database of 414 clinical trials testing chemotherapy regimens for this cancer, extracting information about patient demographics, study characteristics, chemotherapy regimens tested, and outcomes. We use this database to build statistical models to predict trial efficacy and toxicity outcomes. We propose models that use machine learning and optimization to suggest regimens to be tested in Phase II and III clinical trials, evaluating our suggestions with both simulated outcomes and the outcomes of clinical trials testing similar regimens. In Part II, we evaluate how well the methodology from Part I generalizes to advanced breast cancer. We build a database of 1,490 clinical trials testing drug therapies for breast cancer, train statistical models to predict trial efficacy and toxicity outcomes, and suggest combination drug therapies to be tested in Phase II and III studies. In this work we model differences in drug effects based on the receptor status of patients in a clinical trial, and we evaluate whether combining clinical trial databases of different cancers can improve clinical trial toxicity predictions. In Part III, we propose a methodology for decision making when multiple mathematical models have been proposed for a phenomenon of interest, using our approach to identify effective population screening strategies for prostate cancer. We implement three published mathematical models of prostate cancer screening strategy outcomes, using optimization to identify strategies that all models find to be effective.
by John Silberholz.
Ph. D.
Madani, S. Y. "Application of carbon nanotubes for cancer treatment." Thesis, University College London (University of London), 2013. http://discovery.ucl.ac.uk/1402742/.
Full textMasalla, S. G., Waal K. De, and H. S. Friedrich-Nel. "Perceptions about cancer treatment : a Bloemfontein perspective." Interim : Interdisciplinary Journal: Vol 9, Issue 1: Central University of Technology Free State Bloemfontein, 2010. http://hdl.handle.net/11462/344.
Full textCancer patients have varying perceptions about their treatment. The aim of the study was to investigate the different perceptions that patients have about their treatment, and how these perceptions are influenced by their social and cultural backgrounds. The impact of these perceptions on patient responses was also investigated. Eighty-five patients were selected for the study and interviewed using a questionnaire to explore their perceptions and the possible impact of these perceptions on their responses to treatment. An analysis of the perceptions is provided.
Zhu, Yanting. "Exploring alternative cytotoxic strategies for cancer treatment." HKBU Institutional Repository, 2014. https://repository.hkbu.edu.hk/etd_oa/65.
Full textWirth, Manfred P., and Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer." Karger, 2002. https://tud.qucosa.de/id/qucosa%3A27540.
Full textReyad, Mariam M., and O. Kravchuk. "Nanoparticles: creating and using in cancer treatment." Thesis, ХНУРЕ, 2021. https://openarchive.nure.ua/handle/document/15689.
Full textElshafae, Said Mohammed Abbas. "Pathogenesis and Treatment of Canine Prostate Cancer." The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1492081831172341.
Full textBispo, Mafalda Alves Fernandes. "Galacto-silicon phthalocyanines for bladder cancer treatment." Master's thesis, Universidade de Aveiro, 2015. http://hdl.handle.net/10773/19029.
Full textA terapia fotodinâmica (PhotodynamicTherapy, PDT) é uma metodologia emergente no tratamento de diversas doenças oncológicas e tem por base o uso de oxigénio molecular, luz e um fotossensibilizador (FS) para seletivamente destruir as células tumorais. Em oncologia, a PDT leva à indução de espécies reativas de oxigénio (reactive oxygen species, ROS) no tecido tumoral, no qual ocorreu previamente o uptake preferencial e/ou a retenção de um FS. As ftalocianinas têm-se vindo a revelar FSs promissores na PDT devido às suas propriedades foto-físicas. Contudo, estes compostos para além de pouco solúveis em água, têm problemas de agregação e de especificidade para os tecidos tumorais. Assim, o trabalho apresentado nesta tese teve como objetivo principal conjugar co-axialmente ftalocianinas de silício (silicon phthalocyanines, SiPcs) com duas moléculas de galactose (SiPcGal2) e com duas unidades dendríticas de galactose (SiPcGal4) para que estes FSs fossem reconhecidos por galectinas (e.g. galectina-1) sobrexpressas em células tumorais. Contudo, os compostos desejados finais não foram obtidos, uma vez que a remoção dos grupos isopropilideno, protetores dos grupos hidroxilo das unidades de galactose, não foi conseguida. Assim, foram avaliadas as propriedades foto-físicas e foto-químicas das SiPcs com as galactoses protegidas, comparando com a SiPc dihidróxido (SiPc(OH)2), de forma a estudar a influência da conjugação co-axial de biomoléculas no core destes tipo de FSs. Infelizmente, a solubilidade das SiPcs em solventes aquosos não foi conseguida, contudo o seu espectro de absorção UV-visível evidenciou elevada absorção a altos comprimentos de onda (650-700 nm), janela espectrofotométrica onde ocorre uma penetração mais profunda da luz nos tecidos. Para além disso, estes FSs demonstraram-se excelentes marcadores fluorescentes, estáveis após irradiação e bons geradores de 1O2. Foram ainda realizados estudos in vitro com o objetivo de validar o seu potencial fotodinâmico no tratamento do cancro da bexiga, sendo que a SiPcGal4 e a SiPcGal2 agregaram nas células, tendo assim um baixo uptake, baixa toxicidade após foto-ativação e baixa produção de ROS. No geral, as SiPcs demonstraram um grande potencial como futuros FSs para a PDT, dado as suas excelentes propriedades foto-físicas, o que nos incentiva na descoberta de novas técnicas que diminuam a sua agregação nas células, como a utilização de bio-formulações estáveis e a desproteção das moléculas de galactose, que também irá aumentar a sua especificidade para células tumorais.
Photodynamic Therapy (PDT) relies on the combination of a photosensitizer (PS), light and molecular oxygen (O2) to generate reactive oxygen species (ROS), which can trigger cell death pathways. In oncology, the PS needs to be preferentially accumulated in cancer cells and a good generator of ROS (especially singlet oxygen, 1O2). Phthalocyanines (Pcs) are promising PSs in PDT due to their photochemical and photophysical properties. However, Pcs present solubility and aggregation problems, as well as low selectivity to the cancer tissue. Therefore, it will be conjugated a silicon phthalocyanine (SiPc) with two galactose molecules (SiPcGal2) and another with two galacto-dendritic units (SiPcGal4), both in axial positions. The aim of that conjugation is to promote the binding of the PS with galactose-binding proteins such as galectins (e.g. galectin-1) which are found to be overexpressed in cancer cells. Nevertheless, the desired compound were not obtained, once the hydrolysis of the isopropylidene galactose-protective groups didn’t work. Thereby, the photophysical and photochemical properties of those two SiPcs with the galactose-protective groups were studied in comparison with the SiPc dihydroxide (SiPc(OH)2), in order to study the SiPc core properties as well as the influence of an axial conjugation of biomolecules. The PSs solubility was compromised in an aqueous solution, however their absorption UV-Visible spectra showed high absorption peaks at a high wavelengths range (650–700 nm), which is the ideal therapeutical window where there is a higher penetration of light into the tissues. Furthermore, these SiPcs demonstrated to be good fluorescence labels, photostable and good 1O2 generators. In vitro studies were performed with the aim of validating them as photodynamic therapeutic agents against bladder cancer cells, however SiPcGal4 and SiPcGal2 aggregated on cells, having a low uptake, phototoxicity and ROS production. Overall, SiPcs have demonstrated a great potential as future PSs for PDT, thanks to their excellent photophysical properties, which prompt us in the discovery of different approaches that diminished their aggregation on cells, such as the incorporation of PSs into bio-stable formulations and the deprotection of the galactose molecules, which will also increase their specificity to tumoral cells.
Keim, Rebecca. "Treatment-Induced Breast Cancer Dormancy and Relapse." VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/3500.
Full textCampbell, Neil Crawford. "Rural factors in cancer treatment and survival." Thesis, University of Aberdeen, 2003. http://digitool.abdn.ac.uk/R?func=search-advanced-go&find_code1=WSN&request1=AAIU177129.
Full textSmeenk, Henri Gerard. "Surgical and adjuvant treatment of pancreatic cancer." [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2008. http://hdl.handle.net/1765/13713.
Full textKim, Hannah Yejin. "Personalised Medicine in the Treatment of Cancer." Thesis, The University of Sydney, 2018. http://hdl.handle.net/2123/20103.
Full textMartinez, De Pinillos Bayona A. "Light-based therapies in prostate cancer treatment." Thesis, University College London (University of London), 2016. http://discovery.ucl.ac.uk/1532467/.
Full textBossaer, John B., and Christian M. Thomas. "Adjuvant Treatment of Newly Diagnosed Breast Cancer." Digital Commons @ East Tennessee State University, 2011. https://dc.etsu.edu/etsu-works/2313.
Full textKhalaf, Rossa, John B. Bossaer, and Elnora N. Spradling. "Individualized Cancer Treatment based on Pharmacogenomics Analysis." Digital Commons @ East Tennessee State University, 2017. https://dc.etsu.edu/etsu-works/2345.
Full textValetti, Sabrina. "Targeted squalenoyl nanomedicines for pancreatic cancer treatment." Thesis, Paris 11, 2014. http://www.theses.fr/2014PA114805/document.
Full textPancreatic cancer is a lethal disease with the worst prognosis among all solid tumors. In the last decades, progresses in pancreatic cancer therapy had remained exceedingly slow and disappointing offering minimal benefits in median survival which remains of less than 6 months and the maximum of 5 years in the 6% of patients. One of the major requirements for a successful cancer therapy is its ability to selectively kill cancer cells with minimal damage to healthy tissues. In this context, a great deal of attention focused on advanced nanoscale systems (i.e., nanomedicines) with the aim to overcome the limits associated to the traditional drug delivery modalities. Nanomedicines can indeed enhance drug properties by (i) offering protection from degradation, (ii) enabling controlled release and distribution and increasing bioavailability while reducing undesired side effects.In the current work we aimed to propose novel nanoscale-based strategies to optimize pancreatic cancer treatment taking into account the specific physio-pathology of this tumor. The first approach relied on the design of a targeted nanomedicine able to specifically bind receptors mainly expressed onto pancreatic cancer cells in order to selectively increase drug accumulation in these cells saving healthy ones.In a second approach, by combining two therapeutic agents in the same nanoparticle we constructed a multi-therapeutic drug delivery system capable to increase the therapeutic index of the combined therapy. In particular, taking advantages from the “squalenoylation prodrug approach”, the research activity of this Ph.D. work lead to the to design of (i) a novel peptide-functionalized squalenoyl gemcitabine nanoparticle and (ii) a tyrosine kinase inhibitor-loaded squalenoyl gemcitabine nanoparticle. Obtained nanoparticles were investigated with respect to their physico-chemical properties and in vitro antitumor activity. The efficacy of peptide-functionalized nanoparticles in impairing tumor growth was assessed in vivo on an experimental model of pancreatic cancer
Kemp, Patrice. "Cancer Treatment Decision Making in Aging Minorities." ScholarWorks, 2019. https://scholarworks.waldenu.edu/dissertations/6342.
Full textBiason, Paola. "Pharmacogenetics of cytochromes in breast cancer treatment." Doctoral thesis, Università degli studi di Padova, 2008. http://hdl.handle.net/11577/3425652.
Full textLa farmacogenetica studia l’impatto di polimorfismi genetici nella variabilità interindividuale dell’effetto terapeutico, in termini di risposta e tossicità, al trattamento farmacologico. Nella definizione del trattamento per il tumore della mammella si tiene conto di numerosi fattori tra cui la condizione ormonale delle pazienti stesse: la presenza di recettori per gli estrogeni a livello tumorale prevede il trattamento con farmaci anti-estrogenici (exemestane) mentre la malattia localmente avanzata o metastatica viene trattata con chemioterapia citotossica (ciclofosfamide). In entrambi i casi, la presenza di alterazioni genetiche a carico dei citocromi P450 (CYP) potrebbe influenzare la terapia in termini di risposta o di sviluppo di tossicità. Lo studio ha previsto l’arruolamento di due gruppi di pazienti sottoposte a terapia farmacologica (ciclofosfamide in regime CMF) o a terapia ormonale (exemestane) per le quali è stato fatto il profilo genetico di alcune particolari isoforme di CYP. Lo scopo dello studio è stato quello di valutare l’effetto dei polimorfismi individuati sull’outcome clinico delle pazienti in modo da fornire delle indicazioni su una possibile “personalizzazione” della terapia in relazione al profilo genetico della paziente. Lo studio si può definire completo per il gruppo di pazienti in trattamento farmacologico in quanto è stato possibile raccogliere i dati farmacodinamici di tossicità e sopravvivenza. Al contrario, per il gruppo in trattamento ormonale l’arruolamento non è stato completato quindi è stato possibile solo avere dei dati preliminari di frequenza dei polimorfismi. Lo scopo principale dello studio è stato quindi quello di valutare l’impatto di polimorfismi a carico dei CYP (siano essi coinvolti nel metabolismo della ciclofosfamide o rappresentino l’enzima target per exemestane) sulla sopravvivenza e sullo sviluppo di tossicità al trattamento. Inoltre, è stato possibile effettuare anche delle correlazioni di tipo caso/controllo per la valutazione del rischio relativo di sviluppo del tumore in relazione alla presenza dei polimorfismi studiati. Sono state quindi individuate le varianti genetiche a carico delle isoforme CYP2B6, CYP2C9, CYP2C19, CYP3A4 e CYP3A5 coinvolte nella bioattivazione della ciclofosfamide e dell’isoforma CYP19 enzima target di exemestane. La genotipizzazione delle pazienti (195 con trattamento farmacologico e 121 con trattamento anti-estrogenico) si è basata su tecniche che utilizzano l’amplificazione del DNA tramite PCR, quali il Restriction Fragment Length Polymorphism (RFLP), l’analisi automatizzata dei frammenti, la tecnologia del Pyrosequencing e la tecnologia TaqMan. I dati clinici di tossicità sono stati valutati da un oncologo medico secondo la classificazione NCI-CTC mentre il dato di sopravvivenza è stato considerato l’Overall Survival. Dati interessanti e significativi sono emersi per il gruppo di pazienti in trattamento farmacologico con ciclofosfamide in quanto è stato possibile valutare le relazioni tra profilo genetico e profilo farmacodinamico. Lo studio ha infatti evidenziato un ruolo significativo dei polimorfismi dell’isoforma CYP2C9 coinvolti nella bioattivazione epatica della ciclofosfamide sia per quanto riguarda la sopravvivenza che la tossicità. La presenza di almeno un allele mutato per il polimorfismo CYP2C9*2 (C430T) è correlata con un maggior rischio di sviluppo di tossicità epatica alla fine del primo ciclo di trattamento. La riduzione di attività enzimatica conseguente alla variazione genica potrebbe determinare una minore bioattivazione del profarmaco con un suo accumulo a livello epatico. Inoltre anche il polimorfismo CYP2C9*3 (A1075C) ha evidenziato un impatto non solo sulla tossicità epatica ma anche sulla sopravvivenza. La presenza di almeno un allele mutato riduce la sopravvivenza probabilmente in relazione alla minore disponibilità di farmaco attivo. Inoltre è emersa una correlazione significativa anche tra la presenza di un polimorfismo a carico di CYP2C19 (G681A) e lo sviluppo di tossicità ematologica severa (grado 3-4) alla fine della terapia. La presenza del polimorfismo è associata ad una riduzione nell’attività metabolica dell’enzima quindi potrebbe spiegare una riduzione nella bioattivazione della ciclofosfamide con sviluppo di tossicità. In conclusione, durante questo lavoro di tesi, sono stati evidenziati interessanti marcatori molecolari che potrebbero avere un valore prognostico nel trattamento del carcinoma della mammella con ciclofosfamide se confermati in una casistica più ampia. L’applicazione di questi parametri nella pratica clinica potrebbe essere utile per progettare una personalizzazione del trattamento basato su specifiche caratteristiche genetiche del paziente con carcinoma della mammella.
Mielcarek, Angelika Maria. "Surface engineered hybrid nanocarriers for cancer treatment." Electronic Thesis or Diss., Université Paris sciences et lettres, 2020. http://www.theses.fr/2020UPSLE033.
Full textMetal-Organic Frameworks nanoparticles (nanoMOFs) are porous crystalline materials of interest for biomedicine applications. Particularly attractive ones are MIL-100(Fe) iron carboxylate nanoparticles (NPs). Despite many advantages, these NPs tend to aggregate in physiological media and accumulate in organs after intravenous administration. In this work, we investigated the impact of different surface modifications route (covalent and non-covalent) on the colloidal stability of MIL-100(Fe) NPs in physiological media and the ability of the coatings to tune the in vivo biodistribution and pharmacokinetics of NPs. We also investigated different synthesis route to decrease the size of the NPs, in a view of reducing the macrophage recognition. Finally, we studied the encapsulation and release of anticancer drug, Methotrexate (MTX), into magnetic core-shell nanoMOFs-iron oxide NPs and the toxicity evaluation of molecules based on C. elegans worms
Lyu, Zhenbin. "Fluorinated supramolecular dendrimer nanosystems for cancer treatment." Electronic Thesis or Diss., Aix-Marseille, 2020. http://www.theses.fr/2020AIXM0404.
Full textCancer is one of the leading causes of death and remains a difficult disease to treat. The application of nanotechnology is widely expected to bring breakthrough and create novel therapeutics for early and precise diagnosis as well as safe and effective treatment in cancer therapy. Dendrimers are ideal systems for nanomedicine by virtue of their uniquely well-defined structure and multivalent cooperativity. In this PhD thesis, we have developed innovative self-assembling supramolecular dendrimer nanosystems carrying specific fluorinated entities for the delivery of drug, nucleic acid therapeutics and imaging agents. Some of the established fluorinated supramolecular dendrimer nanosystems showed particularly interesting properties for drug encapsulation, nucleic acid delivery and bioimaging with favorable biodistribution profile. In particular, the fluorinated entities also offer the unique opportunity for in vivo 19F magnetic resonance imaging (MRI). Collectively, our innovative fluorinated supramolecular dendrimer nanosystems constitute promising platforms for biomedical applications in cancer treatment
Lyu, Jun Fang. "Discovery of cholesterol trafficking inhibitors as novel anti-angiogenic and anti-cancer agents." Thesis, University of Macau, 2018. http://umaclib3.umac.mo/record=b3953967.
Full textWirth, Manfred P., and Michael Fröhner. "Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133551.
Full textDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich